The remaining four SMAD4 wild‐type primary PDTs harbored KRASG12D (PDT2,5), KRASG12V (PDT4) or exon 4 KRASA146T (PDT3) mutations and exhibited tumor‐suppressive effects upon TGF‐β1 treatment. This evidence concerns the gene SMAD4 and neoplasm.